Skip to content

Comparison of Outcomes of Complex Abdominal Aortic Aneurysm Treatment

Comparison of Endovascular and Open Repair of Juxta- and Pararenal Abdominal Aortic Aneurysm on Short- and Long-term Clinical Outcomes

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04773223
Enrollment
925
Registered
2021-02-26
Start date
2011-01-01
Completion date
2022-01-01
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Juxtarenal Aortic Aneurysm, Pararenal Aneurysm

Brief summary

Background: Open repair remains the gold standard for fit patients with complex AAA. In the past decade, an evolution of devices, design, components, and delivery systems expanded the application of EVAR in these challenging anatomies. Fenestrated stent-grafts are now commercially available for the repair of complex AAA in the United States and Europe. Initial reports have demonstrated a high technical success rate, low renal dysfunction rate, and low morbidity and mortality, with promising short- and long-term results. Other reports have shown excessive morbidity and mortality with fenestrated EVAR (FEVAR). Studies comparing endovascular and open repair are sparse, especially when it concerns long-term outcomes. There are till nowadays only two propensity score-matched studies, one showing worse short-term and another long-term clinical outcome for fenestrated-branched EVAR (F/BEVAR) over open surgical repair (OSR). Aim: The aim of this study will be to compare F/BEVAR versus open AAA repair on short- and long-term clinical outcomes for the treatment of juxta- and pararenal AAA. Methodology: This is a prospective cohort study from the four high-volume AAA repair centers: Belgrade/Serbia, Bologna/Italy, Milan/Italy, Dijklander/Netherland, Amsterdam/Netherland, and Helsinki/Finland. Data will be collected on demographics, baseline comorbidities, AAA parameters (diameter and localization), laboratory values, intra-, and postoperative data. Follow-up examinations (clinical visits and color duplex ultrasonography, CT scans) will be performed 1, 6, and 12 months after the intervention, and annually thereafter. Propensity score analysis will be performed by matching open repair patients to endovascularly treated controlling for demographics and baseline comorbidities. Endpoints: Primary endpoints are all-cause mortality and the freedom from aortic-related reintervention. The secondary endpoint is the 30-day complication rate, especially acute kidney injury according to the RIFLE criteria.

Detailed description

Background Endovascular abdominal aortic aneurysm repair (EVAR) has gained widespread acceptance in the treatment of patients with abdominal aortic aneurysms (AAA). Prospective randomized trials (RCTs) have demonstrated several short-term advantages over open repair such as less blood loss, operative time, hospital stay, morbidity, and mortality. The applicability of EVAR is limited by the presence of inadequate neck or involvement of the visceral arteries. Thus consequently open AAA repair is now being performed primarily for complex aortic anatomies, such as juxtarenal and pararenal aneurysms. Open repair remains the gold standard for fit patients with complex AAA. In the past decade, an evolution of devices, design, components and delivery systems expanded the application of EVAR in these challenging anatomies. Fenestrated stent-grafts are now commercially available for the repair of complex AAA in the United States and Europe. Initial reports have demonstrated a high technical success rate, low renal dysfunction rate and low morbidity and mortality with promising short- and long-term results. Other reports have shown excessive morbidity and mortality with fenestrated EVAR (FEVAR). Studies comparing endovascular and open repair are sparse, especially when it concerns long-term outcomes. There are till nowadays only two propensity score-matched studies, one showing worse short-term and another long-term clinical outcome for fenestrated-branched EVAR (F/BEVAR) over open surgical repair (OSR). Vascular surgeons are therefore left with a paucity of data to guide decision-making. Study objectives: 1. Primary aim: Compare Kaplan-Meier freedom from aortic related reintervention and all-cause mortality rate between endovascular and open repair group Primary endpoint: Kaplan-Meier survival rate and Kaplan-Meier aortic related reintervention rate after the patient recruitment ends 2. Secondary aim: compare short term outcomes in terms of 30-day complications rate, especially acute kidney injury according to the RIFLE criteria Secondary endpoint: 30-day complications rate, especially acute kidney injury according to the RIFLE criteria Inclusion criteria: * All patients (over 18 years of age) with a history of juxta- and pararenal AAA repair from January 2011 to January 2021 * All management strategies will be included (endovascular and open) Exclusion criteria: * Patients who are pregnant * Patients who are under 18 years of age * Patients who have ruptured AAA * Patients with thoracoabdominal aortic aneurysm (ThAAA) * Patients who have a mycotic AAA * Patients with connective tissue disorder Sample size To ensure sufficient statistical power to answer hypothetical questions, approximately 700 subjects will be entered into the database. Aortic-related reintervention rate is the primary endpoint being used to calculate the sample size. Assuming a difference of 7% in the late reintervention rate between endovascular and open repair, 221 patients would be required in each arm to achieve a statistical power of 85% at p=0.05. With two arms (endovascular versus open), assuming a 20% rate of missing data, a total N of 550 patients is required. Research Design This is a prospective study including patients treated for juxta- and pararenal AAA from 2011 through 2021 treated at six different vascular surgery centers: 1. Clinic for Vascular and Endovascular Surgery, Belgrade, Serbia 2. Department of Vascular Surgery, Policlinico S. Orsola-Malpighi, Bologna, Italy 3. Department of Vascular Surgery, San Raffaele Hospital, Milan, Italy 4. Department of Vascular Surgery, Dijklander Ziekenhuis, Hoorn, Netherlands 5. Department of Vascular Surgery, Amsterdam University Hospital, Amsterdam, Netherlands 6. Department of Vascular Surgery, Helsinki Unversity Hospital, Helsinki, Finland Procedures Involved The study does not involve any patient contact and will not impact the care that patients receive. Data regarding the patients will be compiled and analyzed to accomplish the proposed study objectives. Data collection will include demographic information, patient-related factors, and comorbidities, diagnostic imaging information, laboratory data, surgical procedure information, complications of the surgery, and outcomes. Multi-Institutional research After the data has been collected at a participating institution, the data will be transmitted to a central analytic center located at the Clinic for Vascular and Endovascular Surgery/Clinical Center of Serbia/Medical Faculty, University of Belgrade. Risks to Subjects As this is a prospective observational study, there is no potential for physical risks to subjects. There is a minimal risk of breach of confidentiality that could occur when patient information is collected and analyzed for the proposed study. However, appropriate measures will be taken to minimize the risk as much as possible. All information recorded will be de-identified. This study will abide by all regulations related to protecting human subjects and protected health information. Potential Benefits to Subjects There is no direct benefit to the subjects. However, future patients with juxta- and pararenal AAA may benefit from improved care as a result of this study. Statistics and Data Analysis Continuous variables will be described using the median and interquartile range or mean and standard deviation. Categorical variables will be described using frequencies and percentages. Group comparisons will be performed by using the Student t-test or Mann-Whitney U test, as appropriate. Categorical data will be expressed as percentages and were compared using the chi-square test or Fisher exact test. Propensity score analysis will be performed by matching endovascular to open surgery group in a 1:1 ratio controlling for demographics, baseline comorbidities, and AAA parameters. Differences will be considered statistically significant at p \< 0.05. The cumulative incidences of all-cause mortality and aortic-related complications will be estimated using the Kaplan-Meier method. Differences between curves will be tested using the log-rank test. Analyses will be done with SPSS software, version 20.0 (SPSS, Chicago, IL, USA). Conflict of Interest The investigators have no conflict of interest to report. Funding Source There are no plans to apply for grants or additional funding. No funding is required for the completion of this study. Publication Plan All research personnel listed on this protocol will be eligible for authorship in any resulting abstracts and publications in accordance with the qualifications outlined by the International Committee of Medical Journal Editors. The order of authors will be determined prior to manuscript development and depend on each individual's contribution to the study.

Interventions

PROCEDUREOpen surgery and complex EVAR due to AAA

There will be two cohorts: 1. Patient undergoing open surgery 2. Patients undergoing complex endovascular repair (fenestrated, chimney, etc.)

Sponsors

Università Vita-Salute San Raffaele
CollaboratorOTHER
Helsinki University Central Hospital
CollaboratorOTHER
Dijklander Ziekenhuis
CollaboratorOTHER
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
CollaboratorOTHER
IRCCS Azienda Ospedaliero-Universitaria di Bologna
CollaboratorOTHER
Clinical Centre of Serbia
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All patients (over 18 years of age) with a history of juxta- and pararenal AAA repair from January 2011 to January 2022 * All management strategies will be included (endovascular and open)

Exclusion criteria

* Patients who are pregnant * Patients who are under 18 years of age * Patients who have ruptured AAA * Patients with thoracoabdominal aortic aneurysm (ThAAA) * Patients who have a mycotic AAA * Patients with connective tissue disorder

Design outcomes

Primary

MeasureTime frameDescription
Aortic Related Reintervention.through study completion, an average of 7 yearIn open surgery this will include patients who were reoperated due to: graft infection, graft thrombosis, pseudoaneurysm formation, secondary AAA rupture. In endovascular group reintervention will include different reasons: endoleak, migration, thrombosis, infection, fracture, secondary AAA rupture.
All-cause Mortalitythrough study completion, an average of 7 yearAny cause of mortality duing follow-up period

Secondary

MeasureTime frameDescription
30-day Acute Kidney Injury30-day acute kidney injuryAcute kidney injury was defined using RIFFLE criteria.

Countries

Serbia

Participant flow

Participants by arm

ArmCount
Open Surgery Group
Patients undergoing open surgery due to juxta/pararenal abdominal aortic aneurysm using transperitonel or retroperitoneal approach.
600
Endovascular Group
Patients undergoing some form of endovascular abdominal aortic aneurysm repair: fenestrated EVAR (FEVAR), branched EVAR (BEVAR), or combination of both.
234
Total834

Baseline characteristics

CharacteristicEndovascular GroupTotalOpen Surgery Group
Age, Continuous73 years
STANDARD_DEVIATION 6.6
71.9 years
STANDARD_DEVIATION 6.9
69.5 years
STANDARD_DEVIATION 7.1
Atrila fibrillation36 Participants126 Participants90 Participants
Body mass index26.7 kg/m2
STANDARD_DEVIATION 3.7
26.7 kg/m2
STANDARD_DEVIATION 3.6
26.9 kg/m2
STANDARD_DEVIATION 3.4
Carotid artery disease35 Participants131 Participants96 Participants
Chronic kidney disease62 Participants229 Participants167 Participants
Chronic obstructive pulmonary disease88 Participants365 Participants277 Participants
Coronary artery disease84 Participants337 Participants253 Participants
Current smoker89 Participants259 Participants170 Participants
Diabetes mellitus45 Participants187 Participants142 Participants
Heart failure29 Participants90 Participants61 Participants
History of malignant disease51 Participants160 Participants109 Participants
Hyperlipidemia144 Participants557 Participants413 Participants
Hypertension210 Participants690 Participants480 Participants
Peripheral arterial disease34 Participants156 Participants122 Participants
Previos stroke/transitory ischaemic attack47 Participants147 Participants100 Participants
Race and Ethnicity Not Collected0 Participants
Sex: Female, Male
Female
25 Participants175 Participants150 Participants
Sex: Female, Male
Male
209 Participants659 Participants450 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
256 / 60091 / 234
other
Total, other adverse events
0 / 6000 / 234
serious
Total, serious adverse events
133 / 60051 / 234

Outcome results

Primary

All-cause Mortality

Any cause of mortality duing follow-up period

Time frame: through study completion, an average of 7 year

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Open Surgery GroupAll-cause Mortality256 Participants
Endovascular GroupAll-cause Mortality91 Participants
Primary

Aortic Related Reintervention.

In open surgery this will include patients who were reoperated due to: graft infection, graft thrombosis, pseudoaneurysm formation, secondary AAA rupture. In endovascular group reintervention will include different reasons: endoleak, migration, thrombosis, infection, fracture, secondary AAA rupture.

Time frame: through study completion, an average of 7 year

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Open Surgery GroupAortic Related Reintervention.44 Participants
Endovascular GroupAortic Related Reintervention.63 Participants
Secondary

30-day Acute Kidney Injury

Acute kidney injury was defined using RIFFLE criteria.

Time frame: 30-day acute kidney injury

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Open Surgery Group30-day Acute Kidney Injury182 Participants
Endovascular Group30-day Acute Kidney Injury39 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026